0001437749-24-022063.txt : 20240702 0001437749-24-022063.hdr.sgml : 20240702 20240702211544 ACCESSION NUMBER: 0001437749-24-022063 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240702 FILED AS OF DATE: 20240702 DATE AS OF CHANGE: 20240702 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HUNT DOUGLAS M CENTRAL INDEX KEY: 0001727172 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35703 FILM NUMBER: 241098062 MAIL ADDRESS: STREET 1: C/O PUMA BIOTECHNOLOGY,INC. STREET 2: 10880 WILSHIRE BOULEVARD, SUITE 2150 CITY: LOS ANGELES STATE: CA ZIP: 90024 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PUMA BIOTECHNOLOGY, INC. CENTRAL INDEX KEY: 0001401667 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770683487 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10880 WILSHIRE BLVD. STREET 2: SUITE 2150 CITY: LOS ANGELES STATE: CA ZIP: 90024 BUSINESS PHONE: (424) 248-6500 MAIL ADDRESS: STREET 1: 10880 WILSHIRE BLVD. STREET 2: SUITE 2150 CITY: LOS ANGELES STATE: CA ZIP: 90024 FORMER COMPANY: FORMER CONFORMED NAME: INNOVATIVE ACQUISITIONS CORP DATE OF NAME CHANGE: 20070601 4 1 rdgdoc.xml FORM 4 X0508 4 2024-07-02 0001401667 PUMA BIOTECHNOLOGY, INC. PBYI 0001727172 HUNT DOUGLAS M C/O PUMA BIOTECHNOLOGY, INC. 10880 WILSHIRE BLVD., SUITE 2150 LOS ANGELES CA 90024 1 See Remarks 1 Common Stock 2024-07-02 4 S 0 4349 3.2685 D 136864 D Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2020. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.2601 to $3.3101, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer. /s/ Gordon Esplin as attorney-in-fact for Douglas M. Hunt 2024-07-02